紫杉醇、吡柔比星和顺铂治疗52例晚期非小细胞肺癌临床观察

Clinical observation of paclitaxel and pirarubicin combined with cisplatin in treatment of 52 cases of advanced non-small cell lung cancer

目的探讨紫杉醇、吡柔比星、顺铂联合方案治疗晚期非小细胞肺癌的疗效。方法52例经病理或细胞学检查证实的Ⅲb～Ⅳ期非小细胞肺癌，采用紫杉醇＋吡柔比星＋顺铂联合化疗。紫杉醇150mg／m^2，静滴，第1天；吡柔比星30mg／m^2，静滴，第1，8天；顺铂20mg／m^2，第1～4天。每30d为一周期，连续3周期。结果CR2例，PR27例，SD19例，PD4例，客观有效率55．8％；中位生存期10．5个月，1年生存率44．0％（23例）。毒性反应为恶心、呕吐、骨髓抑制，经预防用药或相应处理后缓解。结论紫杉醇＋吡柔比星＋顺铂联合化疗非小细胞肺癌疗效肯定，毒副反应可以耐受。

Objective To explore the efficacy of paclitaxel and pirarubicin combined with cisplatin in treatment of advanced non-small cell lung cancer. Methods Fifty-two cases of Ⅲ b-Ⅳ-stage non-small cell lung cancer confirmed by pathological or cytological examination were treated with paclitaxel and pirarubiin combined with cisplatin ：paclitaxel 150 mg/m^2, intravenous drip on the first day, pirarubicin 30 mg/m^2 intravenous dirp on the first and eighth days and cisplatin 20 mg/m^2 from 1 st to 4th day. Each 30days constituted a cycle and 3 successive cycles were given. Results There were CR in 2 cases ,PR in 27 cases ,SD in 19 cases. Objective effective rate was 55.8% ,median survival time was 10.5 months and 44.0% （23cases） had one year survival time. Toxicity actions were nausea, vomiting, bone marrow suppression, which were relieved after preventive medication or corresponding treatment. Condusion Paclitaxel and pirarubicin combined with cisplatin have definite efficacy in treatment of advanced non-small cell lung cancer and its toxic side reactions axe tolerable.